![]()
|
|
|
Epigenetics: Half of the picture (PART 1)
July 2012
SHARING OPTIONS:
There are a couple schools of thought on how diseases begin.
In modern genetics, science says that
issues with our genes will govern whether or not we get sick in the future.
Remember hearing a few years back about how the entire human genome is now
“mapped?” This map can tell us a lot about disease.
For example, there are two breast cancer genes that can be
tested for now. You may soon be able to evaluate your own genome through an
at-home test.
The field of epigenetics, on the other hand, involves changes
that impact our DNA, but are not guided by inheritance. These are guided by
other factors, such as environment.
In every article describing the leaders in the field,
perhaps no institution is more prolific than Johns Hopkins University. One of
this academic institution’s “rock-star docs” is Dr. Stephen Baylin, a physician,
who tops most lists of the giants in the field. Baylin, a physician, is a prolific researcher and
has published widely on the subject.
Google the topic “epigenetics,” and it
won’t be long before you encounter his name.
Cancer is still one of the most intractable diseases known
to man—yet Baylin is hopeful that the emerging field of epigenetics is spawning
fresh hope for a cure, and not just “someday.”
Baylin also provides the neatest and most concise
explanation of epigenetics: “Think of DNA as the hard drive of the cell,” he
says. “Epigenetics is the software package.”
When it comes to the ever-evolving world of stem cell
research, stem cells are important to epigenetics because they have unique
epigenetic characteristics that make them different from other cells. If stem
cells lose their own epigenetic programming, they are no longer stem cells.
They might become a differentiated cell or even a cancer cell. Many drugs are
known to target the so-called “epigenome” of cells, and science is pursuing how
to use these drugs to control cell behavior. That includes stem cells.
In this, the first part of a two-part series on trends in
stem cell research, we will examine the intersection where stem cells and
epigenetics meet, and how scientific progress in this field will yield the
development of therapies.
How do epigenetic
changes happen?
Epigenetics controls nearly every aspect of the biology of
every type of stem cell.
Epigenetics regulates if the information in DNA can be
turned into some sort of action. Cells have machinery that turns the
information stored in DNA into functional RNAs and proteins, but it is
epigenetics that determines whether that machinery is allowed to do its job.
Epigenetics has two main elements: DNA methylation and
histone modifications. These elements control how the DNA is structured, and
the structure of DNA determines its function.
DNA methylation is a modified form of DNA typically
associated with a resting state. Thus, DNA methylation is a type of epigenetic
function that turns down the “thermostat” of DNA activity.
Histone modifications manifest themselves in a wide variety
of ways. They either ramp up DNA or tone it down. What the histones do to the
DNA structure depends on how they are modified.
All of these changes directly determine how active the DNA
is in specific regions, such as in the genes. But science is years away from
these therapies making the jump to clinical use—in most cases.
At the recently concluded American Society of Clinical
Oncology (ASCO) conference, a small but growing number of presentations were
made about epigenetic research. In the daily conference briefings, several
commentators took note of posters and presentations on some issues in
epigenetics, including applications in pediatrics. Most of these presentations
were at the very beginnings of clinical investigation, but they addressed both
liquid and solid-tumor cancers, including breast, prostate and colorectal
cancers, as well as T-cell lymphoma.
Types of stem cells
There are several key types of stem cells. These types have
different benefits and challenges—some political and some chemical. Science is
racing to plug these stem cells into epigenetic opportunities that control
various disease states.
Stem cells fall into four basic types, with two different
mechanisms of action. Stem cells can be either pluripotent or multipotent. The
two key types being pursued now are mesenchymal stem cells (MSCs) or induced
pluripotent stem cells (iPSCs). MSCs are found in bone marrow, adipose tissue
(or fat), umbilical cord blood or peripheral blood. These cells can become new
bone or cartilage, fat, muscle or pancreatic beta cells. These cells, like
iPSCs, have differentiation potential, meaning that they can turn into any type
of cell. IPSCs, though, have various sources and can become any adult cell
type.
Epigenetics is important for stem cells because of cellular
reprogramming. When scientists make iPSCs, they are reprogramming the epigenome
of a non-stem cell into that of a stem cell. Remarkably, the entire cell now
takes on the identity of a stem cell.
The epigenome guides
cell behavior
The cell, in turn, has no choice but to accept these changes
and either alter its behavior or die. Of course, the process does not always go
as one might hope, and sometimes, since epigenetic changes are not complete,
cellular reprogramming is not complete. Instead of iPSCs, you get pre-iPSCs, or
any of many other cell types.
To learn more about the basics of epigenetics, we spoke with
Dr. Michael Skinner, a basic science researcher at Washington State University.
Skinner’s research in the field of epigenetics has been widely published for
more than 20 years, but just recently, is he finding his phone ringing more
often due to a building interest in epigenetics.
He’s a systems biologist—he studies environmental
epigenetics and reproductive effects of substances on development and function
on molecular, cellular and physiological levels. Skinner is also basic science
researcher. His research projects investigate how different cell types in
animal tissue interact and communicate to regulate cellular growth and
differentiation. His area of emphasis is reproductive biology, so he’s hunting
for the very basic epigenetic changes that occur right after sperm meets egg.
He conducts tests in animal models that can demonstrate that there may be a
reason to look further to prove or disprove a hypothesis in humans.
More recently, Skinner and colleagues have turned their
attention to the ability of environmental factors to act on gonadal development
to cause epigenetic transgenerational, adult-onset disease and influence areas
of biology such as evolution. This has now become a predominant research thrust
in his lab. His basic research projects involve the investigation of how
different cell types in a tissue interact and communicate to regulate cellular
growth and differentiation, with emphasis in the area of reproductive biology.
After a finding in Skinner’s lab, the investigation picks up
with an environmental toxicologist.
In genetics, changes passed down through generations come
from DNA. In epigenetics—back to Baylin’s software reference—changes can switch
depending on some other factor. Software packages can be updated, upgraded and
loaded to replace what was there before or add something new. What Skinner’s
work is telling us is that environmental exposure that suggests epigenetic
exposure can ripple through generations. In scientific parlayance, this is
known as epigenetic transgenerational inheritance.
Many of the chemicals widely in use today span three
generations of use in our environment.
For example, Skinner has researched vinclozolin, a popular
fruit and vegetable fungicide known to disrupt hormones and have effects across
generations of animals. This is the research he did with the rats and their third-generation
descendants, and his findings suggest that stress and anxiety effects seen in
the newest generation resulted from changes in the grandparents.
“The ancestral exposure of your great-grandmother alters
your brain development to then respond to stress differently,” Skinner recently
told ScienceDaily. “We did not know a
stress response could be programmed by your ancestors’ environmental
exposures.”
Skinner has published widely on this topic. He’s published
on transgenerational effects of environmental factors, such as pesticides,
plastics and environmental compounds, showing significant amplification of the
impact and health hazards of these chemicals over time. The transgenerational
nature suggests that a permanent epigenetic alteration of the germ-line in the
subjects studied has taken place.
Skinner says he has studied a half-dozen compounds that are
found in the environment and considered common due to human activity. Some of
his most remarkable work includes studying the compound Bisphenol A (BPA), a
component of plastic. At the request of the military, he studied jet fuel—a
hydrocarbon and another widespread chemical.
The jet fuel Skinner studies is an aviation fuel known as
JP8. What that study was looking for was a suggestion of a negative biological
result from the practice of spraying JP8 onto dusty roads around military bases
to compact the dust.
JP8, just to be clear, is very different that the stuff you
pump into your gas tank. The study of JP8 in animals found the same
transgenerational link to basic biological changes that the pesticide study
did.
In addition to effects on reproduction, numerous other
adult-onset diseases are observed, including cancer, prostate disease, kidney
disease, immune abnormalities and behavior effects. Further characterization of
this phenomena and its impact on disease etiology and evolutionary biology is
in progress, by Skinner and others.
Basically, Skinner says, epigenetic changes happen at the
very basic levels of life. When a zygote is formed biologically, the cells
demethylate for a time, where changes that are not dictated by DNA can occur.
Demethylation is one of the critical concepts. In that
process, the cell stands waiting. Aside from Skinner’s pointing out that this
happens right after conception, demethylation is being studied for other
opportunities.
For example, at ASCO, a paper was presented about testing
targeted demethylation to overcome resistance to epidermal growth factor
blocking agents in colorectal cancer. Again, this peels back a layer of common
understanding of taking a medicine with a known behavior to cure
disease—science is boring down into how diseases alter or take hold of our
cells.
Code: E071229 Back |
|
||
|
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|